Details checkedClinical trial listing onlyCheckedregistry

AUDIOWOLF Sodium Valproate Study in Wolfram Syndrome

Also known as: Depakine, Depakine Chrono, VPA, Sodium valproate, AUDIOWOLF, NCT04940572

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Unknown

Target Gene

—

Route / Mode

Oral

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

France

Population

genetic, syndromic, adult, pediatric

Trial IDs

Mechanism

Phase 2 open-label study evaluating daily oral sodium valproate/Depakine in patients with monogenic Wolfram syndrome, a syndromic condition with hearing-loss relevance.

Indications

Hearing Loss Sensorineural Hearing Loss

Notes

Verified as a real institution-led AUDIOWOLF Phase 2 sodium valproate/Depakine study in Wolfram syndrome. It is hearing-adjacent through syndromic disease context rather than a dedicated hearing-loss product program, and the registry overall status is Unknown.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT04940572

Open

Key Events

2021-11-26

Registry lists actual study start for AUDIOWOLF sodium valproate study

Clinical Trials (1)

NCT04940572

Data Checks